Editorial draft — not for publication yet. Methylphenidate content needs review by a qualified UK healthcare professional before publication. This page is general information and is not advice about an individual prescription.

In short

Methylphenidate is a prescription stimulant used in ADHD care and sometimes for narcolepsy. NICE recommends it as one first-line ADHD medicine option for children aged 5 and over and young people, and one option for adults. It is not an anxiety medicine, study aid or insomnia treatment. Standard and modified-release products differ, and treatment requires clinical assessment and monitoring.

Brand-specific product guides for Methylphenidate: Ritalin brand guide, Alaradate brand guide, Methyphen brand guide. These brand pages are separate from the generic medicine guide.

What is Methylphenidate used for?

Methylphenidate is a prescription central nervous system stimulant. NHS information describes use for ADHD and sometimes narcolepsy. NICE guidance, product licensing and release formulations differ by age, indication and exact product; a clinician with relevant expertise should select and monitor treatment.

  • ADHD: methylphenidate is a recommended medicine option within specialist-led UK care
  • Narcolepsy: NHS information says it is sometimes used, but the exact product and indication must be checked
  • Not a treatment for anxiety, ordinary tiredness, exam performance, appetite suppression or insomnia
  • Standard and modified-release forms have different product instructions and should not be switched casually

NICE recommends methylphenidate as a first-line pharmacological option for children aged 5 years and over and young people with ADHD, and methylphenidate or lisdexamfetamine for adults after appropriate assessment.

NICE recommends baseline and ongoing monitoring during ADHD medicine treatment, including pulse, blood pressure, weight and—among children and young people—height and growth.

How does it work?

Methylphenidate is a stimulant that affects dopamine and noradrenaline signalling involved in attention and behaviour. Its clinical effects and duration vary by person, dose and release formulation; a simplified mechanism does not predict an individual response.

How to take Methylphenidate

  1. Follow the directions on your own dispensing label and the leaflet for the exact methylphenidate product supplied to you.
  2. Do not assume standard tablets and modified-release tablets or capsules have the same timing, food instructions or duration.
  3. Do not share methylphenidate, change brands or formulation, double a missed dose, or use it for studying or sleep without prescriber advice.
  4. Keep follow-up appointments for review of benefit, adverse effects, pulse, blood pressure and weight or growth as appropriate.

Important: Use the instructions on your own prescription or medicine label. Doses and directions can differ between people and products.

Side effects

Common effects

Headache, reduced appetite, stomach discomfort, nausea, restlessness and trouble sleeping can occur. Effects may vary by brand and formulation.

Urgent warning signs

Call 999 for chest pain, seizure, collapse, severe allergic reaction or another life-threatening symptom. Seek prompt advice for fast or irregular heartbeat, hallucinations or marked mood changes.

Warnings and interactions

  • Tell the prescriber about heart problems, high blood pressure, mental-health conditions, epilepsy, tics, pregnancy plans and all medicines or supplements.
  • Do not take methylphenidate with an MAOI or within 14 days after stopping one; ask a pharmacist about other possible interactions.
  • Methylphenidate is a controlled medicine. Use only your prescription, do not share it, and keep it securely stored.
  • Do not drive or operate machinery if dizzy, sleepy, blurred in vision or unable to focus.
  • Do not change or stop treatment on your own. Contact the clinician responsible for your ADHD or sleep-care plan.

Methylphenidate is prescription-only and is controlled as a Class B drug and Schedule 2 controlled drug in the UK. Check current official guidance for a specific legal or travel question.

Methylphenidate for ADHD: NICE treatment context

NICE recommends methylphenidate as a first-line medicine option for children aged 5 and over and young people with ADHD. For adults, NICE recommends methylphenidate or lisdexamfetamine as first-line options when symptoms remain significantly impairing after environmental modifications have been reviewed.

Medication should follow appropriate assessment by a clinician with ADHD expertise. The choice and review plan depend on the individual, product, release type and response.

Narcolepsy, anxiety and sleep questions

NHS information says methylphenidate is sometimes used for narcolepsy, but product indications differ. It is not an anxiety medicine or insomnia treatment; sleep difficulty can be a side effect. Do not use it to self-treat tiredness, anxiety, sleep or studying.

NICE says people with ADHD and coexisting anxiety are generally offered the same ADHD medication choices as other people with ADHD. This does not mean methylphenidate treats anxiety itself; clinicians should assess symptoms and monitor treatment.

Standard tablets, modified release and brand differences

Methylphenidate products include standard and modified-release tablets or capsules. Brands can differ in how they release medicine, food instructions and duration, so NHS guidance advises checking before a brand switch.

Incepta lists Alaradate 10 as a methylphenidate hydrochloride 10 mg tablet in Bangladesh. That brand listing does not make every methylphenidate formulation equivalent or establish UK authorisation of a specific overseas pack.

Monitoring appetite, weight, pulse and blood pressure

NICE recommends monitoring effectiveness and adverse effects, pulse and blood pressure before and after dose changes and every 6 months, plus weight monitoring; height and growth should be tracked in children and young people.

Common effects can include headache, reduced appetite and sleep difficulty. Keep scheduled follow-ups and report persistent or serious effects to the prescriber.

Prescription and controlled-drug status in the UK

Methylphenidate is prescription-only, Class B and Schedule 2 in the UK. It must only be used by the person it was prescribed for and should be stored securely.

This ingredient-level classification does not verify a Bangladesh product or establish that a particular Alaradate pack is authorised for UK supply. Check the exact product with the MHRA or a UK pharmacist.

Alaradate 10 is a Bangladesh brand listing for methylphenidate

Incepta’s Bangladesh product leaflet identifies Alaradate 10 as a tablet containing methylphenidate hydrochloride 10 mg and separately mentions an oral solution. The source describes that manufacturer’s product information; it does not authenticate a particular pack or settle UK authorisation.

Read the separate Alaradate guide for brand-specific questions. Use this methylphenidate guide for the active ingredient and UK treatment context.

Frequently asked questions

What is methylphenidate used for?

NHS information describes use for ADHD and sometimes narcolepsy. NICE recommends it in specific ADHD treatment pathways after assessment.

Is methylphenidate used for anxiety or sleep?

It is not an anxiety or insomnia medicine. It may cause sleep difficulty; ADHD with coexisting anxiety needs an individual clinical plan.

Is methylphenidate a controlled drug in the UK?

Yes. It is prescription-only, Class B and Schedule 2.

Can I switch between methylphenidate brands?

Do not switch yourself. Formulations and release profiles may differ; ask your prescriber or pharmacist to confirm a suitable product.

What is the generic name of Alaradate 10?

Incepta’s product information identifies methylphenidate hydrochloride 10 mg per Alaradate 10 tablet.

Explore the detailed methylphenidate guides

Each guide answers a different practical question. Advice is specific to methylphenidate and should be checked against your own product leaflet and prescription.

Sources and review

This draft was checked against the sources below on 2 October 2026. It still requires review by a qualified UK healthcare professional review before publication.

Editorial status: Clinical review required before publication.